Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians. Each assay is validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians, whose clinical expertise enables test options that improve patient care and increase efficiency.
Mayo Clinic Laboratories innovates at the speed of medical advancement and offers full-spectrum testing across the oncological arena. From broad, next-generation sequencing (NGS) panels like MayoComplete, which examines more than 500 genes for variations associated with solid tumors; to advanced fluorescence in situ hybridization (FISH) testing for monitoring chronic lymphocytic leukemia; to polymerase chain reaction (PCR) for single genes evaluation; our molecular and cytogenetic assays span the oncological spectrum, providing insights on common and rare disease to advance clinical trials and therapeutic development.
In addition to accessing our clinically available tests, Mayo Clinic BioPharma Diagnostics partners can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.
Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.
Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.
Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.